Accord Healthcare
Accord Healthcare is a young and dynamic pharmaceutical company, involved in the development, manufacturing and distribution of pharmaceutical products to more than 70 countries globally.
ADVERSE DRUG
REACTION
REPORT
GROWTH’S IN OUR NATURE
Accord Healthcare is one of the fastest growing generic pharmaceutical companies in the UK & Ireland.
Acquiring Actavis UK and Ireland in 2017 facilitates Accord’s ambition to become a top 5 pan-EMENA generics company by 2021 and have developed a specialty products commercialisation capability.
TRULY MULTINATIONAL
Accord has one of the most extensive sales, marketing and distribution networks in Europe. Headquartered from UK, Accord now supplies products to close to 65 EMENA markets.
A COMPLETE APPROACH
Accord’s vision is to be involved in all aspects of bringing pharmaceuticals to patients. Our activities today encompass the entire pharmaceutical value chain and so create a truly integrated offering.
EUROPEAN FOCUS
Accord currently has a portfolio comprising nearly 7000 product approvals in Europe. We operate a pan European commercial footprint with direct presence in all major EU markets.
News
Accord and other leading voices in the pharmaceutical and financial industry debate how to drive consistent and long-term growth
In November 2018, at the House of Lords, Accord partnered Generics bulletin to bring influential
Accord UK leading the conversation on how biosimilars can improve access to effective cancer treatments
Cancer is one of the biggest global healthcare challenges facing clinicians today. The rising cost of treatments can affect patients’ access to affordable, effective treatments.
Accord Healthcare is dedicated to improving the lives of patients, both in the UK and across the world, through their generics and biosimilar portfolio. Accord have been engaging with healthcare professionals and NHS commissioners at two key events to start the conversation on the role that biosimilars can play in increasing access to effective, affordable cancer medicines.